A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma

• Published in: International journal of cancer Vol. 147; no. 11; pp. 3152 - 3159
• Main Authors: Lewis, Elizabeth C., Kraveka, Jacqueline M., Ferguson, William, Eslin, Don, Brown, Valerie I., Bergendahl, Genevieve, Roberts, William, Wada, Randal K., Oesterheld, Javier, Mitchell, Deanna, Foley, Jessica, Zage, Peter, Rawwas, Jawhar, Rich, Maria, Lorenzi, Elizabeth, Broglio, Kristine, Berry, Donald, Saulnier Sholler, Giselle L.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.12.2020; Wiley Subscription Services, Inc
• Subjects: Cancer; Cancer Therapy and Prevention; Child, Preschool; Children; DFMO; Disease-Free Survival; Eflornithine - administration & dosage; Eflornithine - therapeutic use; Female; high‐risk neuroblastoma; Humans; Immunotherapy; maintenance; Maintenance Chemotherapy; Male; Medical prognosis; Medical research; Neuroblastoma; Neuroblastoma - drug therapy; Prognosis; Short Report; Standard of Care; Survival; Sympathetic nervous system; Treatment Outcome; maintenance; high-risk neuroblastoma; DFMO

Neuroblastoma is a sympathetic nervous system tumor, primarily presenting in children under 6 years of age. The long‐term prognosis for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapy. This report provides an update to a phase II trial evaluating DFMO...